Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer-Reference-Cited by-同舟云学术

Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer

Published:2007-07-25 Issue:31 Volume:104 Page:12837-12842
ISSN:0027-8424
Container-title:Proceedings of the National Academy of Sciences
language:en
Short-container-title:Proceedings of the National Academy of Sciences

Author:

Odunsi K.,Qian F.,Matsuzaki J.,Mhawech-Fauceglia P.,Andrews C.,Hoffman E. W.,Pan L.,Ritter G.,Villella J.,Thomas B.,Rodabaugh K.,Lele S.,Shrikant P.,Old L. J.,Gnjatic S.

Publisher

Proceedings of the National Academy of Sciences

Subject

Multidisciplinary

Reference28 articles.

1. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

2. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

3. Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes

Cited by 222 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells;Expert Review of Vaccines;2024-09

2. Adoptive T cell therapy for ovarian cancer;Gynecologic Oncology;2024-07

3. Navigating immunotherapy for ovarian cancer: current landscape and future perspectives;Journal of Cancer Metastasis and Treatment;2024-06-26

4. The potential value of cancer‐testis antigens in ovarian cancer: Prognostic markers and targets for immunotherapy;Immunity, Inflammation and Disease;2024-06

5. Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities;Signal Transduction and Targeted Therapy;2024-05-22